October 2020, Gennisium Pharma grants exclusive distribution rights to AxxessBio in Asia for Gencebok®.
Gencebok® (caffeine citrate) is indicated for the treatment of primary apnea of premature newborns. Caffeine citrate is the standard treatment for this conditon.
Apnea in preterm infants is common in babies born at less than 34 weeks’ gestation. This is due to the immaturity of the breathing centers in the baby’s brain. Caffeine citrate stimulates the part responsible for breathing allowing the infant to resume breathing.
According to the World Health Organization, an estimated 15 million babies are born too early every year, that is more than 1 in 10 babies. Preterm birth remains the single biggest cause of neonatal death globally and is the second biggest cause of all deaths under 5 years of age despite a reduction in mortality over the past two decades.
AxxessBio and Gennisium Pharma aim to collaborate for building up a dedicated business for neonatology and prematurity therapeutic area in Asia.
Gennisium Pharma is a new European Specialty Pharma Company based in Paris, France. It is dedicated to the development, registration and commercialization of special medicines for Neonatology with global reach. The company mission is to provide health care practitioners and neonatal intensive care units with novel and suitable formulations of medicines needed to prevent or treat neonatal diseases and conditions.
For more information on Gennisium and its products, please visit http://gennisium.com/.
